Drug export legislation -- last efforts
Attempts to create an eleventh hour biotechnology export bill out of the efforts for drug legislation over the last two years faded during the week of Oct. 13-17. By the end of the week, Hill discussions returned to attempts to revive again a drug export bill. PMA has said no to any compromise that entails cooperating with a worldwide drug labeling study.
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 26 January.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.
The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.